Psyence Biomedical Ltd Stock Today
| PBM Stock | USD 3.51 0.17 5.09% |
Performance0 of 100
| Odds Of DistressOver 81
|
Psyence Biomedical is selling at 3.51 as of the 29th of November 2024; that is 5.09 percent up since the beginning of the trading day. The stock's lowest day price was 3.12. Psyence Biomedical has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Psyence Biomedical Ltd are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 30th of October 2024 and ending today, the 29th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 25th of January 2024 | Category Healthcare | Classification Health Care |
Pacific Booker Minerals Inc. engages in the exploration of mineral properties in Canada. The company has 16.7 M outstanding shares of which 823.87 K shares are at this time shorted by investors with about 0.71 days to cover. More on Psyence Biomedical Ltd
Moving against Psyence Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Psyence Stock Highlights
| CEO Director | Neil MD | |||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||
| Psyence Biomedical can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Psyence Biomedical's financial leverage. It provides some insight into what part of Psyence Biomedical's total assets is financed by creditors. | ||||||||||||||||||||||||||||||||||||
Psyence Biomedical Ltd (PBM) is traded on NASDAQ Exchange in USA. It is located in 121 Richmond Street West, Toronto, ON, Canada, M5H2K1 and employs 6 people. Psyence Biomedical is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a total capitalization of 2.6 M. Psyence Biomedical runs under Biotechnology sector within Health Care industry. The entity has 16.7 M outstanding shares of which 823.87 K shares are at this time shorted by investors with about 0.71 days to cover.
Psyence Biomedical Ltd has about 281.63 K in cash with (2.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.02.
Check Psyence Biomedical Probability Of Bankruptcy
Ownership AllocationPsyence Biomedical owns a total of 16.7 Million outstanding shares. Psyence Biomedical has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Psyence Ownership Details
Psyence Biomedical Historical Income Statement
Psyence Stock Against Markets
Psyence Biomedical Corporate Management
| Taryn Vos | General Counsel | Profile | |
| Tony Budden | Chief Officer | Profile | |
| MaryElizabeth Gifford | Executive Impact | Profile | |
| Warwick CordenLloyd | Chief Officer | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Psyence Biomedical Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Psyence Biomedical. If investors know Psyence will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Psyence Biomedical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.82) | Return On Assets (1.26) |
The market value of Psyence Biomedical is measured differently than its book value, which is the value of Psyence that is recorded on the company's balance sheet. Investors also form their own opinion of Psyence Biomedical's value that differs from its market value or its book value, called intrinsic value, which is Psyence Biomedical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Psyence Biomedical's market value can be influenced by many factors that don't directly affect Psyence Biomedical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Psyence Biomedical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Psyence Biomedical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Psyence Biomedical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.